Document is current
Any future updates will be listed below
-
Authors
Yang, Yuzhe https://orcid.org/0000-0002-7634-8295
Yuan, Yuan https://orcid.org/0000-0002-6609-0542
Zhang, Guo
Wang, Hao https://orcid.org/0000-0002-7308-938X
Chen, Ying-Cong
Liu, Yingcheng https://orcid.org/0000-0001-7356-0699
Tarolli, Christopher G.
Crepeau, Daniel
Bukartyk, Jan
Junna, Mithri R.
Videnovic, Aleksandar
Ellis, Terry D.
Lipford, Melissa C.
Dorsey, Ray
Katabi, Dina https://orcid.org/0000-0003-4854-4157
- License Information
-
More Information
Article History
Received: 17 November 2021
Accepted: 5 July 2022
First Online: 22 August 2022
Competing interests
: C.G.T. has received research support from NINDS and Biosensics. T.D.E. has received research support from the National Institutes of Health, Michael J. Fox Foundation and MedRhythms Inc. T.D.E. has received honorarium for speaking engagements, educational programming and/or outreach activities through the American Parkinson Disease Association, the Parkinson’s Foundation, the Movement Disorders Society and the American Physical Therapy Association. R.D. has received honoraria for speaking at American Academy of Neurology, American Neurological Association, Excellus BlueCross BlueShield, International Parkinson’s and Movement Disorders Society, National Multiple Sclerosis Society, Northwestern University, Physicians Education Resource, LLC, Stanford University, Texas Neurological Society and Weill Cornell; received compensation for consulting services from Abbott, Abbvie, Acadia, Acorda, Alzheimer’s Drug Discovery Foundation, Ascension Health Alliance, Bial-Biotech Investments, Inc., Biogen, BluePrint Orphan, California Pacific Medical Center, Caraway Therapeutics, Clintrex, Curasen Therapeutics, DeciBio, Denali Therapeutics, Eli Lilly, Grand Rounds, Huntington Study Group, medical-legal services, Mediflix, Medopad, Medrhythms, Michael J. Fox Foundation, MJH Holding LLC, NACCME, Neurocrine, NeuroDerm, Olson Research Group, Origent Data Sciences, Otsuka, Pear Therapeutic, Praxis, Prilenia, Roche, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Sutter Bay Hospitals, Theravance, University of California Irvine and WebMD; research support from Abbvie, Acadia Pharmaceuticals, Biogen, Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation and Wave Life Sciences; editorial services for Karger Publications; and ownership interests with Grand Rounds (second opinion service). D.K. received research funding from NIH and the Michael J. Fox Foundation. D.K. is a cofounder of Emerald Innovations, Inc., and serves on the scientific advisory board of Janssen and the data and analytics advisory board of Amgen. The remaining authors declare no competing interests.
